Connection
Vernon Holers to Neuroprotective Agents
This is a "connection" page, showing publications Vernon Holers has written about Neuroprotective Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.175 |
|
|
|
-
Rich MC, Keene CN, Neher MD, Johnson K, Yu ZX, Ganivet A, Holers VM, Stahel PF. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains. Neurosci Lett. 2016 Mar 23; 617:188-94.
Score: 0.116
-
Leinhase I, Schmidt OI, Thurman JM, Hossini AM, Rozanski M, Taha ME, Scheffler A, John T, Smith WR, Holers VM, Stahel PF. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp Neurol. 2006 Jun; 199(2):454-64.
Score: 0.059